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Abstract
Based on their proposed metabolic effects, we examined whether fish oil (FO) and SCFA, alone or in combination, accelerate weight loss
and the resultant metabolic improvements. Obesity was induced in male C57BL/6J mice by high-energy feeding for 10 weeks. The mice
were transferred to a low-fat diet (2·5w%) for 4 weeks, the source of fat being either FO, a lard–safflower oil mix (control), or both types
combined with SCFA. Weight, fasting insulin, tissue and serum lipid concentrations, as well as mRNA amount of genes related to adipose
inflammation and hepatic fat oxidation were determined. All groups lost weight and showed reduced fasting insulin concentrations and
reduced liver TAG. However, weight loss on the control-fat diet caused significant increase in hepatic and cardiac NEFA. Substituting
20 % of the fat with SCFA increased weight loss by 48 % and reduced fasting insulin 1·5-fold more than the no-SCFA diets. It furthermore
significantly increased the amount of mRNA for PPAR-a, and decreased the mRNA amount for NF-kB in the liver and white adipose tissue.
The FO diets enhanced improvement of tissue lipid levels. Thus, FO improved liver TAG and NEFA levels compared with weight loss on
the control diet. Combining FO and SCFA further reduced tissue NEFA accumulation. In conclusion, we found that dietary SCFA had a
significant impact on gene expression in the liver and adipose tissue, and that the effect of FO on tissue NEFA content was modified
by SCFA. Thus, interactions between fatty acids should be considered when studying the effects of specific fatty acids.
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Dietary fatty acid chain length and degree of unsaturation are
believed to influence the development of insulin resistance
and n-3 long-chain (LC)-PUFA are particularly interesting
due to their proposed anti-inflammatory and lipid-modulating
effects. Weight loss is also expected to improve insulin sensi-
tivity, restore normal function of the adipose tissue and reduce
the level of inflammatory mediators. We therefore hypoth-
esised that the addition of fish oil (FO) to a weight loss diet
could improve the recovery of healthy metabolic function
due to combined beneficial effects, including a potential
increase in the rate of weight loss as indicated from studies
with human test subjects(1–3).
Several recent studies indicate that pro-inflammatory
mediators produced in the adipose tissue promote the devel-
opment of insulin resistance(4). Fat-laden adipocytes excrete
mediators that attract and activate macrophages(5–7), which,
in turn, excrete a number of inflammatory molecules including
TNF-a(8). TNF-a has been implicated to directly attenuate
the insulin response in skeletal muscle cells, adipocytes and
hepatocytes(9–11) and several molecular mechanisms have
been suggested to link TNF-a to insulin resistance; for example,
a direct inhibition of insulin-receptor autophosphorylation(11).
Furthermore, it has been shown that TNF-a can increase lipo-
lysis, causing an increased flow of NEFA from adipocytes to
non-adipose tissues, which is also expected to reduce insulin
sensitivity in both skeletal muscles and the liver(12).
A beneficial effect of FO on adipose inflammation in db/db
mice on a high-fat diet has been shown by Todoric et al.(13).
Furthermore, Krebs et al.(14) found additional improvements
in metabolic risk factors in women who consumed FO while
losing weight. A plausible mechanism behind this effect
could be that n-3 LC-PUFA or their metabolites activate
PPAR, which leads to the induction of anti-inflammatory
pathways. PPAR-g activation has been shown to reduce the
production of TNF-a(15). PPAR-g and PPAR-a activation has
also been shown to inhibit the activation of NF-kB, which is
a key pro-inflammatory regulator(16). PPAR-a is also a key
regulator of genes involved in lipid oxidation and its activation
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Abbreviations: Ctrl, control; FO, fish oil; GPR, G-protein-coupled receptor; LC-PUFA, long-chain-PUFA; SREBP-1c, sterol regulatory element binding
protein-1c.
British Journal of Nutrition (2011), 106, 1449–1456 doi:10.1017/S0007114511001917
q The Authors 2011
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
by dietary n-3 LC-PUFA may thus reduce the lipid load in
non-adipose tissue and thereby increase insulin sensitivity(17).
The inclusion of low-energy fat in exchange for normal fat
may be another way to enhance recovery during weight loss.
Low-energy fat of the Salatrim type contains high amounts of
SCFA (acetate and propionate), which reduces the energy con-
tent to about 21 kJ/g compared with 38 kJ/g in normal dietary
fat(18). Furthermore, SCFA have been shown to induce the
expression of PPAR-a and reduce the expression of NF-kB
in a cell model(19), indicating that SCFA might have anti-
inflammatory activity. Interestingly, acetate, the main organic
acid in Salatrim, was found to exert strong anti-inflammatory
activity through the activation of the G-protein-coupled recep-
tor 43 (GPR43; also called NEFA receptor-2)(20). GPR43 has
been identified as a specific receptor for SCFA, and is mainly
expressed in white and brown adipose tissue, the large intes-
tine, dendritic cells and granulocytes(20,21). In the white adipose
tissue, GPR43 activation has been implicated in the regulation
of lipid and glucose homeostasis and is today exploited as a
promising drug target for the treatment of insulin resistance
and type 2 diabetes(22). Furthermore, it was also recently
shown that activation of GPR43 in immune cells is required
for normal resolution of certain inflammatory responses(21).
Thus, combining Salatrim with FO may result in synergism
from the concomitant increase in PPAR-a expression and
increased availability of its n-3 LC-PUFA agonists, as well as
the anti-inflammatory effects and metabolic improvements in
adipose tissue induced by the activation of GPR43.
The primary hypothesis of the present study was that obese
mice on a hypoenergetic diet enriched with FO show
improved rate of weight loss and greater improvements in
metabolic risk factors compared with mice on a similar diet
low in n-3 LC-PUFA. We furthermore explore the hypothesis
that SCFA from Salatrim and n-3 LC-PUFA from FO have syner-
gistic beneficial effects on metabolic function, enhancing
the rate of which it returns to a lean phenotype during
weight loss. Metabolic function was assessed by weight,
fasting insulin, tissue lipid content and transcription of genes
related to inflammation and lipid turnover.
Methods
Animals and diets
A total of forty-eight male C57BL/6J mice weighing 22·3 (SD 1·1) g
(Charles River Laboratories International, Wilmington, MA, USA)
were randomised into six groups. A lean reference group
(lean) was kept on standard diet 1324 from Altromin (Lage,
Germany) for the entire feeding period. In the five remaining
groups, obesity was induced by feeding a high-energy diet
for 10 weeks (60 energy% fat) (D12492; Research Diets,
New Brunswick, NJ, USA) and by the addition of 15 w%
sucrose to drinking-water. Following the weight gain period,
one group of mice continued on the high-fat diet to serve as
an obese reference group (obese), while four groups were
switched to ad libitum low-energy diets for 4 weeks (2·5 w%
fat added to powdered C1056 diet from Altromin). There
was no difference in the average weight of the five obese
groups after the weight gain period; the average was 35 g
compared with 26 g in the lean reference group. The weight
loss diets differed in fatty acid composition (Table 1) by the
addition of either cod liver oil (FO) or a control (Ctrl) mix
of lard and safflower oil (Ctrl) alone or with the exchange
of 25 w% of the fat for Salatrim (FO þ Salatrim, Ctrl þ
Salatrim) (the Salatrim was a gift from DANISCO, Brabrand,
Denmark). The macronutrient composition in the four
weight loss diets was identical with 611 g/kg carbohydrates,
25 g/kg fat, 172 g/kg protein, 142 g/kg free amino acids and
41 g/kg fibre. The amount of fat added to the weight loss
diets corresponded to the upper levels of a realistic daily FO
intake for humans. Thus, the 2·5 w% equals 6 energy%,
which corresponds to a daily intake of 15 g FO for a person
consuming 10 000 kJ/d. The mice were housed in groups of
four in wire cages at 20–228C, humidity between 45 and
65 %, and a 12 h light cycle. All handling and use of animals
in the present study were approved by The Danish Animal
Experiments Inspectorate and were carried out according to
the guidelines of ‘The Council of Europe Convention for the
Protection of Vertebrate Animals used for Experimental and
other Scientific purposes’.
Physiological and biochemical measurements
Weight was recorded weekly and fasting insulin was measured
after 10 and 14 weeks. All mice were killed after 14 weeks
by anaesthetisation (0·11 ml/25 g body weight of Ketaminol
mixed with Narcoxyl 1000:125; Intervet Danmark AS,
Skovlunde, Denmark) followed by a cardiac puncture from
where all the blood was drawn. The blood was left to clot
at room temperature for 20 min and the serum was collected
after centrifugation. The heart, liver and adipose tissue were
removed immediately and quickly frozen in liquid N2 before
transfer to a 2808C freezer. Small fractions of the liver and adi-
pose tissue were treated with RNAlater (Invitrogen, Taastrup,
Table 1. Fatty acid composition of the four weight loss diets that were
fed to obese mice for 4 weeks*
Fatty acid (g/100 g) Ctrl Ctrl þ S FO FO þ S
2 : 0 – 6·9 – 6·9
3 : 0 – 0·6 – 0·6
14 : 0 2·0 1·5 4·6 3·6
16 : 0 25·4 22·2 11·2 10·8
16 : 1n-7 2·1 1·5 6·7 5·1
18 : 0 12·9 25·1 2·4 14·6
18 : 1n-9 34·7 25·7 23·0 17·7
18 : 1n-7 2·4 1·7 3·9 3·0
18 : 2n-6 17·3 12·3 4·2 3·3
18 : 3n-3 0·8 0·6 3·1 2·5
18 : 4n-3 – – 2·3 1·8
20 : 1n-9 0·6 0·5 10·1 7·6
22 : 1n-11 – – 6·8 5·2
20 : 5n-3 – – 7·3 5·7
22 : 5n-3 0·1 0·1 0·9 0·7
22 : 6n-3 0·1 0·1 10·5 8·3
Ctrl, control diet; FO, fish oil diet; FO þ S, 25 w% of the normal fat was exchanged
for Salatrim.
* The amount of each fatty acid is given as g/100 g of total fatty acids. The total fat
content was 2·5 w%.
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Denmark) according to the manufacturer’s recommendations,
prior to freezing and later RNA isolation. Serum concentrations
of insulin were analysed using ELISA kits (Mercodia
AB, Uppsala, Sweden). Serum concentrations of TAG and
NEFA were measured using kits from Wako Chemicals
(Neuss, Germany) and a Cobas Mira auto-analyzer (Roche,
Basel, Switzerland). Lipids were extracted from the tissue,
the serum and the feed using the Folch procedure with
the addition of nonadecanoic acid, dinonadecanoyl-
glycerophosphorylcholine and triheptadecanoyl as internal
standards before extraction(23). Tissue phospholipids, NEFA
and TAG were separated using preparative TLC; methyl
esters of the lipids were prepared from the TLC scrapings or
directly from the lipid extract of the serum and diets and
separated and quantified using GLC as described earlier(24).
RNA extraction and real-time quantitative PCR
Total RNA was isolated from the hepatic and adipose tissue
using TRIzol (Invitrogen) and mRNA was further isolated
from the total RNA by the use of mMACS mRNA isolation kit
(Miltenyi Biotec, Bergisch Gladbach, Germany). Reagents
for first strand synthesis, as well as primer sets for real-time
quantitative PCR, were purchased from Superarray (Frederick,
MD, USA) in the form of commercial kits including CYBR
green master mix for real-time detection. Actb, Gapdh and
HSP90AB1 were used as reference genes. A Biometra Tperso-
nal thermocycler (Biometra, Goettingen, Germany) was used
for first strand production, and a Bio-Rad iCycler iQ5
was used for PCR amplification and detection (Bio-Rad,
Copenhagen, Denmark). The thermocyclers were programmed
according to the recommendations from Superarray. Melting
curve analysis was performed to check that only one target
was amplified.
Statistics
All data are presented as group mean and standard deviations.
GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA,
USA) was used for statistical analysis, and significance was
set at a 0·05. A two-way ANOVA was performed in order to
assess the effect of fat type and Salatrim in the four weight
loss diets, comparing data from these four groups only. If
the ANOVA result showed a significant interaction, two-sided
t-tests were computed to assess the differences between the
individual groups. Data from the obese and lean reference
groups are included in all graphs and tables for comparison.
Results
Weight loss and fasting insulin
All weight loss groups continuously lost weight and the obese
reference group continued to gain weight between weeks 10
and 14 (Fig. 1(A)). Fasting insulin was changed accordingly in
all groups (Fig. 1(B)). Furthermore, there was a significant
correlation between the change in weight and change in fast-
ing insulin (r 2 0·73, P,0·0001). Salatrim caused a significant
increase in weight loss, whereas the weight loss and sub-
sequent change in fasting insulin in the FO and Ctrl groups
did not differ (Fig. 1).
Effects on lipid content and composition
The analysis of EPA and DHA amounts in liver TAG showed
that the FO groups responded to the treatment with about
sixteen times more EPA and five times more DHA incorporation
compared with the Ctrl groups (Fig. 2(A)). Analysis of the adi-
pose tissue content of EPA and DHA showed that even
though thef net flux of fatty acids during weight loss is assumed
to be away from the adipose tissue, incorporation of the
fatty acids from the FO diets had taken place (Fig. 2(B)). The
hepatic phospholipid fatty acid composition and adipose
tissue total fatty acid composition can be found in the online
supplementary material (http://www.journals.cambridge.org/bjn).
The concentration of TAG in the liver was reduced in both
FO groups with no additional effect of Salatrim (Table 2). The
serum concentration of NEFA was increased in the FO groups
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Fig. 1. The (A) weight change and (B) change in fasting insulin during the
weight-loss phase (weeks 10–14) in the four weight loss groups and the lean
and obese reference groups. Values are means and standard deviations, n 8.
The lean and obese groups serve as reference groups for comparison and
were not included in the statistical analyses. Statistical analysis was per-
formed as a two-way ANOVA, using fish oil and Salatrim as variables. For
both weight change and change in fasting insulin, two-way ANOVA showed
an effect of Salatrim (P,0·02). a,b Mean values with unlike letters are signifi-
cantly different (P,0·05). Ctrl, control diet; FO, fish oil diet; FO þ S, 25 % of
the normal fat was exchanged for Salatrim.
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but the serum concentration of TAG was not affected by any of the
treatments (Table 2). It is noteworthy that, in both Ctrl groups
weight loss induced a substantial increase in hepatic concentrations
of NEFA compared with both the obese and the lean reference
groups (Fig. 3(A) and (B)). FO reduced this weight loss-induced
liver accumulation of NEFA, and there was a pronounced inter-
action between FO and Salatrim, which reduced NEFA even further
(Fig. 3(A)). Analysis of cardiac NEFA accumulation also showed sig-
nificant interaction between FO and Salatrim, which resulted in
lower NEFA concentrations in the FO þ S group compared with
the three other weight loss groups (Fig. 3(B)).
Liver and adipose tissue mRNA amounts
The addition of Salatrim to the diets resulted in significantly
higher levels of PPAR-a mRNA and lower levels of mRNA
for the P65 subunit of NF-kB in both the liver (Fig. 4 (A)
and (B)) and adipose tissue (the supplementary material for
this article can be found at http://www.journals.cambridge.
org/bjn) compared with the effect of the weight loss diets
without Salatrim. The Salatrim groups also had lower levels
of sterol regulatory element binding protein-1c (SREBP-1c)
mRNA in the liver (Fig. 4(C)). TNF-a mRNA in the adipose
tissue tended to be lower in the Salatrim groups compared
with the pure FO and Ctrl groups (the supplementary material
for this article can be found at http://www.journals.
cambridge.org/bjn). Neither FO nor Salatrim significantly
reduced the level of CD68 mRNA, which was used as a
marker for macrophage infiltration in the adipose tissue
(the supplementary material for this article can be found
at http://www.journals.cambridge.org/bjn). No significant
group differences were found in hepatic mRNA amounts of
the SREBP-1c-regulated enzymes; fatty acid synthase and
acetyl-CoA carboxylase, which together produce fatty acids
from acetyl-CoA (the supplementary material for this article
can be found at http://www.journals.cambridge.org/bjn).
Nor were there any significant differences in the mRNA
amount of stearoyl CoA desaturase-1 – a key lipogenic
enzyme, or in the mRNA amounts of three PPAR-a-regulated
fatty acid oxidative enzymes; acyl-CoA synthetase (catalyses
an initial step in long-chain fatty acid catabolism), the per-
oxisomal b-oxidation enzyme acyl-CoA oxidase, and the
microsomal v-hydroxylase cytochrome P450 4A10 (the sup-
plementary material for this article can be found at http://
www.journals.cambridge.org/bjn). The relative mRNA amounts
of adipokines and genes associated with inflammation and
energy metabolism can be found in the supplementary
material at http://www.journals.cambridge.org/bjn. Salatrim
treatment significantly reduced adipose mRNA levels of
TGF-b, plasminogen activator inhibitor-1, leptin, resistin and
the insulin receptor, and FO treatment also reduced adipose
resistin mRNA.
Table 2. Concentrations of TAG and NEFA in the liver and serum after 4 weeks weight loss diet
(Mean values and standard deviations, n 8)
Lean† Obese† Ctrl Ctrl þ S FO FO þ S P ‡
Lipid* Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD FO Salatrim Interaction
Hepatic TAG (mg/g) 28 7 111 49 65 17 74 13 54 18 61 14 0·04
Hepatic NEFA (mg/g) 1·2 0·3 1·2 0·2 2·4 0·4 3·1 0·5 1·9 0·3 1·5 0·2 0·0005
Cardiac TAG (mg/g) 22 18 10 4·4 16 5·3 13 4·3 16 6·1 7 3·8
Cardiac NEFA (mg/g) 0·46 0·18 0·53 0·14 1·52 0·60 2·19 0·94 1·43 0·63 0·75 0·28 0·02
Serum TAG (mmol/l) 0·50 0·14 0·51 0·12 0·86 0·34 0·58 0·19 0·85 0·18 0·92 0·24
Serum NEFA (mmol/l) 0·36 0·10 0·45 0·13 0·55 0·16 0·46 0·09 0·60 0·11 0·63 0·19 0·04
Ctrl, control diet; FO, fish oil diet; FOþ S, 25 % of the normal fat was exchanged for Salatrim.
* Extracted from serum and tissue from fasted animals.
† The lean and obese groups serve as reference groups for comparison and are not included in the statistical analyses.
‡ Results from the two-way ANOVA with P,0·05 and the treatment, FO or Salatrim that caused the effect.
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Fig. 2. The percentage of EPA ( ) and DHA ( ) in the (A) liver and (B) adi-
pose tissue TAG as a percentage of total fatty acids in TAG. Otherwise as
in Fig. 1. a,b Mean values with unlike letters are significantly different. Ctrl,
control diet; FO, fish oil diet; FO þ S, 25 % of the normal fat was exchanged
for Salatrim.
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Discussion
In the present study we have investigated how specific groups
of dietary fatty acids and their interactions affect the rate of
weight loss, metabolic function and risk factors related to
the development of the metabolic syndrome in mice.
In our study, the inclusion of FO to a weight loss diet did not
affect the rate of weight loss or fasting insulin. This is contrary
to studies that have shown that the inclusion of n-3 LC-PUFA
to a weight loss diet leads to increased rate of weight loss
in humans(1–3) and reduced fasting insulin in rodents(25).
However, anti-obesity effects are not a consistent finding in
humans as other studies report no effect of n-3 LC-PUFA on
the rate of weight loss(26,27), whereas in rodents, the anti-obes-
ity as well as insulin-reducing effects of n-3 LC-PUFA have
been highly consistent during weight gain(28–33). However,
as our primary focus was to study the effects of a FO intake
realistic for a human population, we have used substantially
lower concentrations than earlier studies. Nakatani et al.(28)
compared the effect on weight gain of different amounts of
FO fed to female C57BL/6J mice, and found that less than
40 energy% FO was insufficient in reducing weight gain sig-
nificantly compared with the no FO control. We gave the
mice 4·5–6 energy% FO, which corresponds to 12–15 g/d of
FO for a person consuming 10 000 kJ/d, and higher intake
might be unrealistic in a human nutritional context.
Furthermore, in contrast to earlier studies when FO was
given during weight gain, we can also expect dilution of the
fatty acids of dietary origin with fatty acids released from
the adipose tissue during weight loss in the present study.
Therefore, it is noteworthy, that the low doses used have
been sufficient to improve hepatic and cardiac lipid status,
proving that FO intake at these relatively low levels also
improves metabolic status during weight loss.
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was exchanged for Salatrim.
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Dietary n-3 LC-PUFA have been shown to prevent the
development of insulin resistance in rodents when obesity is
induced by a high-energy diet(29,33–35), but the effect of
administering n-3 LC-PUFA to obese animals during weight
loss has, to our knowledge, not previously been investigated.
A study by Ramel et al.(36) indicated that physiological doses
of FO (3 g/d) during weight loss would improve insulin
sensitivity in humans, and in the present study we wanted
to investigate the potential mechanisms for this effect. We
hypothesised that the proposed anti-inflammatory effects of
n-3 LC-PUFA could lead to a reduction of the inflammatory
state of the adipose tissue, and that the activation of hepatic
PPAR-a by n-3 LC-PUFA could induce the transcription of
fat-oxidising enzymes and thus reduce hepatic lipid accumu-
lation. Both of these effects were expected to improve insulin
sensitivity, but no difference was seen in fasting insulin after
4 weeks on a FO diet compared with the Ctrl group that
did not consume FO. Total macrophagal infiltration in the
adipose tissue was assessed by the amount of mRNA encoding
CD68, a macrophage surface receptor, and this was also not
reduced by FO treatment. Total macrophagal infiltration,
however, does not give information on the activation state
of the adipose tissue macrophages, but as anti-inflammatory
effects of FO on the amount of mRNA encoding TNF-a or
NF-kB P65 were not found, an effect on the distribution
between inflammatory M1- and anti-inflammatory M2-tissue
macrophages is unlikely.
Hepatic NEFA and TAG accumulation was reduced by FO
relative to the Ctrl fat, and in both cardiac and hepatic tissue
the combination of FO and SCFA was particularly efficient in
reducing NEFA accumulation. This shows that inclusion of
FO and SCFA in weight loss diets might be a feasible strategy
to optimise the improvement in tissue lipid status during
weight loss. The increased load of NEFA in tissues is strongly
linked to the accumulation of lipotoxic fatty acid derivatives,
such as acyl-CoA, ceramide and diacylglycerol, which have
been suggested to be part of the aetiology of both insulin
resistance and CVD(37,38). Hence, the increased load of cardiac
and hepatic NEFA in the weight-loss groups given Ctrl fat,
constitute a metabolic risk that, at least in mice, can be
reduced through intervention with appropriate dietary fat
during a weight-loss programme. The lipid-lowering effect
of FO is consistent with the expected effect of n-3 LC-PUFA
on PPAR-a and SREBP-1c in the liver. However, we did not
find a significant increase in the mRNA amount of PPAR-
a-regulated hepatic fat-oxidising enzymes that could explain
this finding. Mori et al.(32) were able to find significant
increases in the mRNA amount and enzymatic activity of
hepatic fat-oxidising enzymes in C57BL/6J mice following
2 weeks on a FO diet. Their setup, however, differed from the
present study as they fed the mice a weight-increasing diet.
In conclusion, we show that a (relatively) low-dose FO
intervention is able to increase the rate of improvement of
liver lipid levels during a weight-loss programme without a
concomitant improvement of glucose tolerance or adipose
inflammation, compared with weight loss on the Ctrl-fat diet.
We also investigated the effect of exchanging 25 w%
of normal fat with Salatrim. This exchange was tried in
combination with both Ctrl fat and FO in order to investigate
the possible synergistic effects of the SCFA from Salatrim and
n-3 LC-PUFA from FO. The weight loss after 4 weeks on
low-energy diets was evident for all mice, but it was signi-
ficantly greater when 25 % of the fat was exchanged for
Salatrim. The change in fasting insulin was highly correlated
to weight change and additional improvements in the Salatrim
groups were probably due to the difference in weight.
However, Salatrim also affected parameters which could
not be explained by the reduced energy intake and increased
weight loss. The amount of PPAR-a mRNA was higher, and
that of NF-kB p65 subunit was lower in both adipose and
hepatic tissues. We were able to show in vivo the effect of
SCFA on the amount of PPAR-a mRNA, which had previously
been shown only in in vitro experiment(19). A higher
expression of PPAR-a could explain the combined effect of
SCFA and n-3 LC-PUFA on hepatic and cardiac NEFA levels.
The transcription of many lipogenic enzymes is controlled
by the transcription factor SREBP-1c, and a reduction in its
activity could also lead to reduced fatty acid accumulation.
We found a significant reduction in the amount of mRNA
encoding this transcription factor following Salatrim treatment,
but again without significant reductions in the amount of
mRNA-encoding lipogenic enzymes under its control.
The source of SCFA in the present study was Salatrim, but
fermentation of fibre by the gut microflora provides a natural
source of SCFA, which has been measured to be 375 mmol/l in
the human portal vein(39). The finding that acetate and pro-
pionate in Salatrim seem to act as systemic transcriptional
regulators therefore has more wide-reaching implications as
it suggests that some of the systemic effects induced by
interventions with pre- or probiotica might be explained by
enhanced production of SCFA. Cell studies have shown
reduced cytokine production following LPS stimulation of
SCFA-treated neutrophils, and SCFA have furthermore been
shown to inhibit the activity of NF-kB in vitro. The present
results, showing lower hepatic and adipose transcription of
NF-kB p65 in the SCFA-treated mice, indicate that SCFA
could also inhibit NF-kB activity in vivo, and that those
anti-inflammatory effects of SCFA could reach the systemic
circulation, although evidence of reduced inflammation was
not found in the present study. Yin et al.(40) have shown
that SCFA treatment reduced IkB (NFkB inhibitor degradation
after NF-kB stimulation in vitro, and it is possible that SCFA
inhibit NF-kB activity by more than one pathway. Systemic
inflammation is associated with the metabolic syndrome, and
it is possible that SCFA mediate some of the beneficial effects
of fibre consumption by its anti-inflammatory properties.
An effect of SCFA on gene transcription could be mediated
by the receptors, GPR41 and GPR43, which are widely distrib-
uted, although most commonly associated with adipocytes
and immune cells(21). SCFA have previously been shown to
signal through these receptors(41).
In conclusion, the addition of FO to a low-fat diet during
weight loss did not reduce adipose inflammation and fasting
insulin. However, exchanging 25 w% of the fat with Salatrim
increased weight loss, lowered fasting insulin and altered
the amount of mRNA encoding three important transcription
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factors, PPAR-a, NF-kB and SREBP-1c, which are central in
inflammatory response and fatty acid metabolism. However,
the most important finding of the present study is the pro-
nounced synergistic effect of FO and Salatrim on tissue
NEFA, since a reduction in available NEFA may affect the con-
centration of lipotoxic fatty acid metabolites that have been
implicated in the development of insulin resistance and CVD.
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